Targeting Angiotensinogen with N-Acetylgalactosamine-Conjugated Small Interfering RNA to Reduce Blood Pressure

Dien Ye, Edwyn O. Cruz-López, Ho Chou Tu, Ivan Zlatev, A. H.Jan Danser*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
21 Downloads (Pure)

Abstract

Blood pressure management involves antihypertensive therapies blocking the renin-angiotensin system (RAS). Yet, it might be inadequate due to poor patient adherence or the so-called RAS escape phenomenon, elicited by the compensatory renin elevation upon RAS blockade. Recently, evidence points toward targeting hepatic AGT (angiotensinogen) as a novel approach to block the RAS pathway that could circumvent the RAS escape phenomenon. Removing AGT, from which all angiotensins originate, should prevent further angiotensin generation, even when renin rises. Furthermore, by making use of a trivalent N-acetylgalactosamine ligand-conjugated small interfering RNA that specifically targets the degradation of hepatocyte-produced mRNAs in a highly potent and specific manner, it may be possible in the future to manage hypertension with therapy that is administered 1 to 2× per year, thereby supporting medication adherence. This review summarizes all current findings on AGT small interfering RNA in preclinical models, making a comparison versus classical RAS blockade with either ACE (angiotensin-converting enzyme) inhibitors or AT1 (angiotensin II type 1) receptor antagonists and AGT suppression with antisense oligonucleotides. It ends with discussing the first-in-human study with AGT small interfering RNA.

Original languageEnglish
Pages (from-to)2256-2264
Number of pages9
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume43
Issue number12
DOIs
Publication statusPublished - 1 Dec 2023

Bibliographical note

Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.

Fingerprint

Dive into the research topics of 'Targeting Angiotensinogen with N-Acetylgalactosamine-Conjugated Small Interfering RNA to Reduce Blood Pressure'. Together they form a unique fingerprint.

Cite this